LAB (LAB)

Market Cap
P/E Ratio
Beta
Dividend Yield
Piotroski 4/9Beneish M -2.84 Clean

Quantitative Summary

Deterministic

Financial health is average: Piotroski 4/9.

Generated deterministically from quant metrics and financial statements. Not a recommendation.

Algorithmic Teardown

AI-Generated

The fundamental economics of LAB reveal a distressed operational profile characterized by a negative ROIC of -16.6% and severe margin compression, with net margins contracting to -87.8%. While the gross margin sits at 49.9%, indicating some pricing power or cost control in direct production, this is entirely offset by massive operating inefficiencies that have dragged overall profitability into deep negative territory alongside a 6.2% revenue decline year-over-year. The DuPont decomposition suggests leverage cannot be compensating for these structural issues, as the return on equity is fundamentally eroded by the loss-making core business. Further corroborating this deterioration are the Piotroski F-Score of 4/9 and Beneish M-Score of -2.84; while a negative M-score typically flags low earnings manipulation risk, it coincides here with clear financial distress rather than aggressive accounting optimization, signaling that the market is grappling with genuine value destruction rather than perceived overstatement.

Valuation metrics are absent from the provided dataset due to the lack of share price or P/E data in the input; consequently, no comparison against historical averages or sector peers can be constructed based on the available information. Without a DCF model's implied growth rate or current fair value estimate derived from these missing inputs, it is impossible to determine if the market is pricing in a turnaround scenario or acknowledging terminal decline. The absence of positive earnings renders traditional multiple-based valuation frameworks inapplicable for assessing relative cheapness or expensiveness at this time.

Risk factors are elevated given the confluence of shrinking revenues and negative returns on invested capital, creating an asymmetric risk-reward profile where downside volatility is likely to outpace any potential recovery catalysts. The Piotroski score indicates a company failing half its nine criteria for financial strength, suggesting deteriorating balance sheet health or declining asset efficiency that could exacerbate liquidity pressures if the trend persists.

Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.

Price Chart with Moving Averages

Loading chart...
SMA 50 SMA 200

Quant Health Deep Dive

4/9
Piotroski F-Score
Average — mixed operational signals
-2.84
Beneish M-Score
Below threshold — no statistical earnings quality concern per Beneish model. Threshold: <-2.22 = below threshold.

Profitability & Value Creation

49.9%
Gross Margin
-87.8%
Net Margin
-16.6%
ROIC
-6.2%
Revenue Growth (YoY)
+46.1%
Earnings Growth (YoY)
-82.6M
Free Cash Flow

Balance Sheet Health

0.34x
Debt / Equity
4.19x
Current Ratio
-3718.3x
Interest Coverage
-85.7M
EBITDA

Earnings Surprise History

Q4
✗ Miss
Est: $-0.04
Act: $-0.05
-19.5%
Q3
✓ Beat
Est: $-0.04
Act: $-0.04
+0.3%
Q2
✗ Miss
Est: $-0.02
Act: $-0.04
-101.5%
Q1
✓ Beat
Est: $-0.03
Act: $0.07
+368.8%

EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.

Underwater (Drawdown from Peak)

How far below the all-time high the price has been over time. Deeper = more pain for holders.

Loading drawdown chart...

Rolling 60-Day Beta vs S&P 500 (VOO)

How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.

Loading beta chart...
Rolling Beta Market (β = 1.0)

Fundamentals

Forward P/E
PEG Ratio
Price/Book
Avg Volume
52W High
52W Low
52W Range Position

ETF Contagion Visualizer

Simulate a price drop in LAB to visualize passive redemption contagion across ETFs and collateral stocks.

LAB Shock
-0%
Est. Passive Redemption
$0
Systemic Risk
STABLE
LABEpicenterVHTETFLLYLow RiskJNJLow RiskABBVMed RiskUNHMed RiskMRKLow Risk
LAB Price Drop (%)0

If LAB (LAB) experiences a significant drawdown, ETF redemptions can create collateral selling pressure on co-held stocks. Our model identifies Eli Lilly & Co. (LLY) as the most exposed collateral stock, sharing 1 ETFs with LAB. This is the "Passive Contagion" effect described in the Inelastic Market Hypothesis.

Contagion model based on shared ETF exposure and constituent weights across 1 tracked ETFs. Estimated selling pressure is a simplified model — actual impact depends on market liquidity, ETF redemption mechanics, and market-maker activity.

LAB Ownership Dynamics

Ticker
LAB

ETFs with Highest LAB Exposure

Float lock-up computed from 2 ETFs tracked by SecuritiesDB. Actual passive ownership is higher (includes mutual funds, pension funds, etc.).

Fails-to-Deliver (FTD) History

SEC-reported settlement failures. Elevated FTDs can indicate high short-selling pressure, operational settlement issues, or naked shorting activity.

DateFailed SharesClose PriceNotional Value
2026-05-14224,733$1.01$226,980.33
2026-05-0764,777$0.97$62,833.69
2026-05-0547,243$0.94$44,408.42
2026-05-0473,904$0.94$69,469.76
2026-04-3098,091$0.89$87,300.99
2026-04-2461,738$0.89$54,946.82
2026-04-2363,587$0.94$59,771.78
2026-04-179,856$0.92$9,067.52
2026-04-13203,839$0.89$181,416.71
2026-04-10396,554$0.91$360,864.14
2026-04-09220,733$0.94$207,489.02
2026-04-08108,537$0.93$100,939.41
2026-04-0726,663$0.89$23,730.07
2026-04-02112,150$0.92$103,178
2026-04-0174$0.92$68.08
2026-03-1856,987$0.98$55,847.26
2026-03-1733,722$0.96$32,373.12
2026-03-1625,908$0.93$24,094.44
2026-03-1335,986$0.93$33,466.98
2026-03-116,352$0.99$6,288.48
2026-02-27127,149$1.17$148,764.33
2026-02-061,000$1.24$1,240
2026-01-285,734$1.48$8,486.32
2026-01-275,836$1.53$8,929.08
2026-01-23100$1.61$161
2026-01-214,350$1.51$6,568.5
2026-01-1630,963$1.58$48,921.54
2026-01-1410,971$1.63$17,882.73
2026-01-09200$1.54$308
2026-01-057,884$1.27$10,012.68

Source: SEC Regulation SHO FTD data. Data is reported with a ~30 day delay. High FTD quantities relative to average daily volume may indicate settlement stress.

Compare LAB to Peers

Quant metrics computed deterministically from financial statements and price data. Updated: N/A.

SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.